In order to bring you the best possible user experience, this site uses Javascript. If you are seeing this message, it is likely that the Javascript option in your browser is disabled. For optimal viewing of this site, please ensure that Javascript is enabled for your browser.

The free consultation period for this content is over.

It is now only available year-round to HFA Silver & Gold Members, Fellows of the ESC and Young combined Members

Clinical characteristics and predictors of one-year outcome in patients hospitalized for heart failure: results from the Polish part of the ESC-HF-Pilot and ESC-HF-LT Registries

Session Rapid Fire 3 - Acute heart failure - From diagnosis to prognosis

Speaker Sonia Borodzicz-Jazdzyk

Event : Heart Failure 2017

  • Topic : arrhythmias and device therapy
  • Sub-topic : Syncope and Bradycardia
  • Session type : Rapid Fire Abstracts

Authors : S Borodzicz (Warsaw,PL), P Balsam (Warsaw,PL), K Ozieranski (Warsaw,PL), M Peller (Warsaw,PL), A Tyminska (Warsaw,PL), A Kaplon-Cieslicka (Warsaw,PL), M Marchel (Warsaw,PL), J Drozdz (Lodz,PL), G Opolski (Warsaw,PL), M Grabowski (Warsaw,PL)

S Borodzicz1 , P Balsam1 , K Ozieranski1 , M Peller1 , A Tyminska1 , A Kaplon-Cieslicka1 , M Marchel1 , J Drozdz2 , G Opolski1 , M Grabowski1 , 1Medical University of Warsaw, 1st Chair and Department of Cardiology - Warsaw - Poland , 2Medical University of Lodz, Department of Cardiology - Lodz - Poland ,

European Journal of Heart Failure ( 2017 ) 19 ( Suppl. S1 ), 198

Introduction: The Heart Failure (HF) Association of the European Society of Cardiology (ESC) created the Heart Failure Pilot Survey (ESC-HF Pilot) and Heart Failure Long-Term Registry (ESC-HF-LT) which are prospective, multicentre, observational registries aimed to evaluate the clinical profile, pharmacotherapy and one-year outcomes of HF patients in the European countries.

Purpose: The aim of the study was to compare the clinical characteristics and one-year outcome, as well as predictors of mortality and hospital readmissions in patients hospitalized for HF enrolled in the ESC-HF-Pilot or ESC-HF-LT Registry.

Methods: The analysis included hospitalized Polish patients enrolled in the ESC-HF-Pilot Registry and in the phase I of the ESC-HF-LT Registry. The primary endpoint (PE) was all-cause death at one year, while the secondary endpoint (SE) was composed of all-cause death or rehospitalization for worsening HF at one year.

Results: The total Polish cohort of both Registries included 2 019 patients. The final analysis consisted of 1 415 inpatients, 650 from the ESC-HF-Pilot and 765 from the ESC-HF-LT Registries. The PE was reached by 209 of the 1361 patients (15.4%); in the ESC-HF-Pilot Registry the PE occurred in 89 of the 650 patients (13.7%), whereas in the ESC-HF-LT Registry the PE was observed in 120 of the analyzed 711 patients (16.9%; p=0.11). The SE occurred in 423 of the 1172 patients (36.1%), including 201 of the 509 patients from the ESC-HF-Pilot Registry (39.5%) and 222 of the 663 patients from the ESC-HF-LT Registry (33.5%; p=0.04). The independent predictors of PE in the total population from both registries were older age, chronic obstructive pulmonary disease (COPD), higher New York Hear Association (NYHA) class at admission, lower serum sodium at admission, support of inotropics during index hospitalization, lower systolic blood pressure (SBP) at discharge, higher heart rate at discharge, and amiodarone at discharge. The prescription of beta-blockers at discharge was associated with significantly decreased mortality. The independent predictors of SE were diabetes, myocardial infarction, NYHA class at admission, lower serum sodium at admission, lower serum potassium at admission, support of inotropics during index hospitalization, use of diuretics intravenously during index hospitalization and lower SBP at discharge.
Conclusions: The results of the present study reveal, that patients hospitalized for HF remain at high risk for adverse outcomes, including death and HF rehospitalization. The recent progress in diagnosis and treatment of HF changes the patients’ clinical profile and frequency of HF readmission.

The free consultation period for this content is over.

It is now only available year-round to HFA Silver & Gold Members, Fellows of the ESC and Young combined Members

Get your access to resources

Join now
  • 1ESC Professional Members – access all ESC Congress resources 
  • 2ESC Association Members (Ivory, Silver, Gold) – access your Association’s resources
  • 3Under 40 or in training - with a Combined Membership, access all resources
Join now

Our sponsors

ESC 365 is supported by Bayer, Boehringer Ingelheim and Lilly Alliance, Bristol-Myers Squibb and Pfizer Alliance, Novartis Pharma AG and Vifor Pharma in the form of educational grants. The sponsors were not involved in the development of this platform and had no influence on its content.

logo esc

Our mission: To reduce the burden of cardiovascular disease

Who we are